The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Long-Term Cardiovascular Mortality in Patients With Differentiated Thyroid Carcinoma: An Observational Study
Abstract
PURPOSE: The primary aim was to study the risk of cardiovascular mortality in patients with differentiated thyroid carcinoma (DTC). Secondary aims were to evaluate all-cause mortality and explore the relation between thyroid-stimulating hormone (TSH; also known as thyrotropin) level and these outcome parameters. PATIENTS AND METHODS: Subjects from two cohorts were retrospectively compared by Cox regression analyses; 524 patients with DTC and 1,572 sex- and age-matched controls from a large population-based study in the same geographic region. RESULTS: Mean age plus or minus standard deviation was 49 ± 14 years. Median follow-up was 8.5 years (interquartile range [IQR], 4.1 to 15.9 years) for patients with DTC and 10.5 years (IQR, 9.9 to 10.9 years) for controls. One hundred patients with DTC (19.1%) died, 22 (4.2%) as a result of cardiovascular disease, 39 (7.4%) as a result of DTC, and 39 (7.4%) as a result of other/unknown causes. Eighty-five controls (5.4%) died, 24 (1.5%) as a result of cardiovascular disease and 61 (3.9%) as a result of other/unknown causes. Patients with DTC had an increased risk of cardiovascular and all-cause mortality (hazard ratios [HRs], 3.35 [95% CI, 1.66 to 6.74] and 4.40 [95% CI, 3.15 to 6.14], respectively, adjusted for age, sex, and cardiovascular risk factors). Within the DTC group, TSH level was predictive for cardiovascular mortality; the adjusted HR was 3.08 (95% CI, 1.32 to 7.21) for each 10-fold decrease in geometric mean TSH level. CONCLUSION: The risk of cardiovascular and all-cause mortality is increased in patients with DTC, independent of age, sex, and cardiovascular risk factors. A lower TSH level is associated with increased cardiovascular mortality, supporting the current European Thyroid Association and the American Thyroid Association guidelines of tempering TSH suppression in patients with low risk of cancer recurrence. Furthermore, patients with DTC may benefit from assessment and treatment of cardiovascular risk factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“thyroid-cancer patients receiving TSH suppressive doses of L-T4 had increased risk of cardiovascular and all-cause mortality (100).”
From Levothyroxine therapy in elderly patients with hypothyroidism (2021) · cites this paper as [100]
Citations
Cites
TNM Classification of Malignant Tumours
Hermanek, P., & Sobin, L. H. (1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,077
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., Correa, C., Cutter, D., Gagliardi, G., Gigante, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209825 · Cited by 3,974
TNM Classification of Malignant Tumours
(2003) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471463752 · Cited by 3,968
Instrumental Variables and GMM: Estimation and Testing
Baum, C. F., Schaffer, M. E., & Stillman, S. (2003) · The Stata Journal Promoting communications on statistics and Stata · doi:10.1177/1536867x0300300101 · Cited by 2,663
Pacini, F., Schlumberger, M. J., Dralle, H., Elisei, R., Smit, J. W. A., Wiersinga, W. M., & _, _. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02158 · Cited by 1,970
Global estimates of cancer prevalence for 27 sites in the adult population in 2008
Bray, F., Ren, J., Masuyer, E., & Ferlay, J. (2012) · International Journal of Cancer · doi:10.1002/ijc.27711 · Cited by 1,893
Papillary and Follicular Thyroid Carcinoma
Schlumberger, M. J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380506 · Cited by 1,619
TNM classification of malignant tumours
Cassoni, A. M. (1998) · Clinical Oncology · doi:10.1016/s0936-6555(98)80120-9 · Cited by 1,202
Outcomes of Patients with Differentiated Thyroid Carcinoma Following Initial Therapy
Jonklaas, J., Sarlis, N. J., Litofsky, D. R., Ain, K. B., Bigos, S. T., Brierley, J. D., Cooper, D. S., Haugen, B. R., Ladenson, P. W., Magner, J. A., et al. (2006) · Thyroid · doi:10.1089/thy.2006.16.1229 · Cited by 693
Parle, J. V., Maisonneuve, P., Sheppard, M. C., Boyle, P., & Franklyn, J. A. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06067-6 · Cited by 669
Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer
Pujol, P., Daurès, J., Nsakala, N., Baldet, L., Bringer, J., & Jaffiol, C. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954034 · Cited by 319
Survival and Death Causes in Differentiated Thyroid Carcinoma
Eustatia‐Rutten, C. F. A., Corssmit, E. P. M., Biermasz, N. R., Pereira, A. M., Romijn, J. A., & Smit, J. W. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1322 · Cited by 287
Biondi, B., & Cooper, D. S. (2010) · Thyroid · doi:10.1089/thy.2009.0311 · Cited by 286
Heerspink, H. J. L., Brantsma, A. H., de Zeeuw, D., Bakker, S. J. L., de Jong, P. E., Gansevoort, R. T., & for the PREVEND Study Group (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn209 · Cited by 249
Self-citationYang, L., Shen, W., & Sakamoto, N. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.4457 · Cited by 190
Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis
Links, T. P., van Tol, K. M., Jager, P. L., Plukker, J. T. M., Piers, D. A., Boezen, H. M., Dullaart, R. P. F., de Vries, E. G. E., & Sluiter, W. J. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00892 · Cited by 142
Self-citationSugitani, I., & Fujimoto, Y. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0161 · Cited by 141
Smit, J. W. A., Eustatia‐Rutten, C. F. A., Corssmit, E. P. M., Pereira, A. M., Frölich, M. A., Bleeker, G. B., Holman, E. R., van der Wall, E. E., Romijn, J. A., & Bax, J. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0620 · Cited by 125
Tools for Analyzing Multiple Imputed Datasets
Carlin, J., Li, N., Greenwood, P., & Coffey, C. (2003) · The Stata Journal Promoting communications on statistics and Stata · doi:10.1177/1536867x0300300302 · Cited by 113
Survival and causes of death in thyroid cancer: a population-based study of 2479 cases from Norway.
Akslen, L. A., Haldorsen, T., Thoresen, S., & Glattre, E. (1991) · PubMed · Cited by 107
Shargorodsky, M., Serov, S., Gavish, D., Leibovitz, E., Harpaz, D., & Zimlichman, R. (2006) · Thyroid · doi:10.1089/thy.2006.16.381 · Cited by 84
van Tol, K. M., Jager, P. L., de Vries, E. G. E., Piers, D., Boezen, H., Sluiter, W. J., Dullaart, R. P. F., & Links, T. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480589 · Cited by 75
Self-citationAbonowara, A., Quraishi, A. U. R., Sapp, J. L., Alqambar, M. H., Saric, A., O’Connell, C. M., Rajaraman, M. M., Hart, R. D., & Imran, S. A. (2012) · Clinical and investigative medicine · doi:10.25011/cim.v35i3.16591 · Cited by 73
Is Thyroid Hormone Suppression Therapy Prothrombotic?
Horne, M. K., Singh, K. K., Rosenfeld, K. G., WESLEY, R. A., Skarulis, M. C., Merryman, P. K., Cullinane, A., Costello, R., Patterson, A., Eggerman, T. L., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0536 · Cited by 66
Abdulrahman, R. M., Delgado, V., Hoftijzer, H. C., Ng, A. C. T., Ewe, S. H., Marsan, N. A., Holman, E. R., Hovens, G. C., Corssmit, E. P. M., Romijn, J. A., et al. (2011) · Thyroid · doi:10.1089/thy.2010.0319 · Cited by 46
Biondi, B. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0585 · Cited by 32
van Dijk, D., Plukker, J. T. M., van der Horst‐Schrivers, A. N. A., Jansen, L., Brouwers, A. H., Kobold, A. C. M., Sluiter, W. J., & Links, T. P. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03885.x · Cited by 14
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- Pujol P, 1996, J Clin Endocrinol Metab, 81, 4318
- Akslen LA, 1991, Cancer Res, 51, 1234
Cited by
Sorted by citations
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Ringel, M. D., Sosa, J. A., Baloch, Z. W., Bischoff, L. A., Bloom, G., Brent, G. A., Brock, P. L., Chou, R., Flavell, R. R., Goldner, W. S., et al. (2025) · Thyroid · doi:10.1177/10507256251363120 · Cited by 891
Carhill, A. A., Litofsky, D. R., Ross, D. S., Jonklaas, J., Cooper, D. S., Brierley, J. D., Ladenson, P. W., Ain, K. B., Fein, H. G., Haugen, B. R., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1346 · Cited by 184
Lebbink, C. A., Links, T. P., Czarniecka, A., Dias, R. P., Elisei, R., Izatt, L., Krude, H., Lorenz, K., Luster, M., Newbold, K. L., et al. (2022) · European Thyroid Journal · doi:10.1530/etj-22-0146 · Cited by 184
Self-citationIto, Y., Onoda, N., & Okamoto, T. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0025 · Cited by 182
Metadata
- Authors
- Klein Hesselink, E. N., Klein Hesselink, M. S., de Bock, G. H., Gansevoort, R. T., Bakker, S. J. L., Vredeveld, E. J., van der Horst-Schrivers, A. N. A., van der Horst, I. C. C., Kamphuisen, P. W., Plukker, J. T. M., Links, T. P., & Lefrandt, J. D.
- Affiliations
- All authors: University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- University Medical Center Groningen (NL)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2013-11-10
- Volume
- 31
- Issue
- 32
- Pages
- 4046-4053
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2142884678
- Cited by
- 183
- References
- 29
- Citations by year
- 2026: 6 · 2025: 20 · 2024: 13 · 2023: 10 · 2022: 16 · 2021: 26 · 2020: 13 · 2019: 11 · 2018: 10 · 2017: 19 · 2016: 12 · 2015: 15 · 2014: 9 · 2013: 3
- FWCI
- 10.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- differentiated thyroid cancer, cardiovascular mortality, all-cause mortality, thyroid-stimulating hormone, TSH suppression, cardiovascular risk factors, cancer recurrence risk, cardiovascular risk stratification, American Thyroid Association guidelines, cardiovascular risk
- MeSH terms
- Cardiovascular Diseases, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Thyroid Neoplasms, Thyrotropin, Proportional Hazards Models, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review